Bard
This article was originally published in The Gray Sheet
Executive Summary
Acquires Angiomed, a Karlsruhe, Germany-based manufacturer of stents, catheters, guide and specialty wires, and biopsy products, for undisclosed terms. Bard says the acquisition will strengthen its position in Germany and Eastern Europe. About half of Angiomed's $40 mil. in 1993 revenues were generated in Germany. "We are excited about Angiomed's metal stent technology which is currently being marketed in urology, radiology, vascular surgery and gastroenterology in both Germany and France," Bard says, adding that "potential coronary applications are under development." Bard plans to consolidate its Munich-based German operation into Angiomed's headquarters in Karlsruhe, where Angiomed employs about 400 people. Some job reductions are anticipated
You may also be interested in...
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.